Chief Financial Officer · Syros Pharmaceuticals, Inc. (SYRS)

Jason Haas

A named executive officer of Syros Pharmaceuticals in every fiscal year CompBrief holds from FY2022 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$833,019

Salary $485,185Stock awards $160,800

FY2022: $1,416,010

5th of 5 named executive officers at Syros Pharmaceuticals by FY2023 total.

5 named officers on file for Syros Pharmaceuticals, FY2023

Jason Haas’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Syros Pharmaceuticals’s whole pay program stands against its peers

  • Syros Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SYRS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 23, 2024 (10-K).

Free

Get Jason Haas’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Jason Haas compensation by year

Syros Pharmaceuticals Summary Compensation Table · all 2 fiscal years held
In US dollars, as Syros Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023
Salary$465,385$485,185
Bonus$0$0
Stock awards$381,258$160,800
Option awards$380,317$0
Non-equity incentive$188,000$185,744
Pension and deferred compensation$0$0
All other$1,050$1,290
Total$1,416,010$833,019

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Syros Pharmaceuticals, Inc. 10-K filed April 23, 2024, accession 0001193125-24-105876, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Syros Pharmaceuticals, Inc. filed document, accession 0001193125-24-105876. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2024.

$1.4M
$833K
FY22
FY23
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU40,000$311,600—
PSU40,000$311,600—
RSU18,875$147,036—
RSU6,000$46,740—
Option6,775—$15.90
Option34,382—$45.40
Option24,875—$6.73

Per the Outstanding Equity Awards at Fiscal Year-End table in Syros Pharmaceuticals, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Syros Pharmaceuticals’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Nancy SimonianFormer President & Chief Executive Officer$1,436,782
Conley CheePresident & Chief Executive Officer$1,041,697
Eric OlsonFormer Chief Scientific Officer$935,768
David RothChief Medical Officer$876,534
Jason Haas · this pageChief Financial Officer$833,019

The full Syros Pharmaceuticals compensation record

free company brief

This page is one person within Syros Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Syros Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jason Haas's compensation dossier · One-time report. No refunds.